EMT markers (E-cadherin, N-cadherin, Vimentin, and Snail) along with stemness markers (CD44, CD133, and SOX2) were significantly less pronounced, indicating that ruxolitinib mediated the disruption of ENC1 effects in CRC cells (Figures 6D,F). The gene discussed is SOX2; the disease is colorectal carcinoma.